Antag Therapeutics
Manufacturing · Denmark · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Ole Maaløes Vej Cobis 3, Copenhagen, Cap...Phone Number
+45 21456537Website
www.antagtx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Antag Therapeutics
Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders. The company's approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology. Antag’s portfolio of GIPR antagonists is inspired by an endogenous GIPR antagonist discovered by the esteemed research teams of Professors Jens Juul Holst and Mette Rosenkilde, extensively studied in numerous human interventional trials.Explore more
Popular SearchesAntag TherapeuticsAntagSIC Code 28,283NAICS Code 32,325Show moreAntag Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Antag Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Antag Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Antag Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Antag Therapeutics has new funding data
Check if Antag Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Antag Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Antag Therapeutics recently announced quarterly report
Click to see if Antag Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Antag Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Antag Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Antag Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Antag Therapeutics.
Antag Therapeutics financials insights
Gather financial insights about Antag Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$84M
Antag Therapeutics Tech Stack
A closer look at the technologies used by Antag Therapeutics
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Antag Therapeutics News & Media
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Copenhagen, Denmark, 21 May 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces the appointment of Philip Just Larsen MD, PhD as Chief Executive Officer (CEO).Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions
Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will deliver an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association® in New Orleans, Louisiana, taking place from 5-8 June 2026. The presentation will feature data from the Company’s first-in-human study of AT7687, its first-in-class Glucose Dependent Insulinotropic PolAntag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
Copenhagen, Denmark, 8 January 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces topline data from two studies evaluating AT7687, its first-in-class GIPR antagonist. These data demonstrate the compelling versatility of AT7687 to enhance the treatment of obesity giving better efficacy potential in combination with other obesity treatments, without impacting tolerability.Innovation and collaboration: Denmark’s vibrant tech environment
Denmark’s tech ecosystem is thriving, particularly in green tech, healthtech, fintech, robotics, and AI. These sectors are supported by robust digital infrastructure, a skilled workforce, and forward-...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Antag Therapeutics
Sign Up For FreeTo access detailed company insights
Antag Therapeutics is a biotechnology company dedicated to developing innovative peptide-based therapies to address obesity and related cardiometabolic disorders. The company's approach is rooted in decades of pioneering research from the University of Copenhagen, with a focus on the complexities of incretin physiology. Antag’s portfolio of GIPR an... Read More
